Comparison of clinical pharmacology of voriconazole and posaconazole
Despite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal infections grows too. This is why there is still a que...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2016-12-01
|
Series: | Contemporary Oncology |
Subjects: | |
Online Access: | https://www.termedia.pl/Comparison-of-clinical-pharmacology-of-voriconazole-and-posaconazole,3,28897,1,1.html |
id |
doaj-c7ce4e251ba8489680f50bc2951fdb09 |
---|---|
record_format |
Article |
spelling |
doaj-c7ce4e251ba8489680f50bc2951fdb092020-11-24T22:38:08ZengTermedia Publishing HouseContemporary Oncology1428-25261897-43092016-12-0120536537310.5114/wo.2016.6459428897Comparison of clinical pharmacology of voriconazole and posaconazoleBeata M. SienkiewiczŁukasz ŁapińskiAnna Wiela-HojeńskaDespite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal infections grows too. This is why there is still a quest for new antifungal drugs as well as for optimization of pharmacotherapy with already registered pharmaceutics. Voriconazole and posaconazole are broad-spectrum, new generation, triazole antifungal agents. The drugs are used in the pharmacotherapy of invasive aspergillosis, Candida and Fusarium infections. Voriconazole is also used in infections caused by Scedosporium . Posaconazole is used in the treatment of coccidioidomycosis and chromoblastomycosis. Besides some similarities, the two mentioned drugs also show differences in therapeutic indications, pharmacokinetics (mainly absorption and metabolism), frequency and severity of adverse drug reactions, drug–drug interactions and dosage. As both of the drugs are used in the treatment of invasive fungal infections in adults and children, detailed knowledge of the clinical pharmacology of antifungal agents is the main factor in pharmacotherapy optimization in treatment of fungal infections. The goal of the article is to present and compare the clinical pharmacology of voriconazole and posaconazole as well as to point out the indications and contraindications of using the drugs, determine factors influencing their pharmacotherapy, and provide information that might be helpful in the treatment of fungal infections.https://www.termedia.pl/Comparison-of-clinical-pharmacology-of-voriconazole-and-posaconazole,3,28897,1,1.htmlvoriconazole posaconazole clinical pharmacology cytochrome P-450 enzyme system drug monitoring |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Beata M. Sienkiewicz Łukasz Łapiński Anna Wiela-Hojeńska |
spellingShingle |
Beata M. Sienkiewicz Łukasz Łapiński Anna Wiela-Hojeńska Comparison of clinical pharmacology of voriconazole and posaconazole Contemporary Oncology voriconazole posaconazole clinical pharmacology cytochrome P-450 enzyme system drug monitoring |
author_facet |
Beata M. Sienkiewicz Łukasz Łapiński Anna Wiela-Hojeńska |
author_sort |
Beata M. Sienkiewicz |
title |
Comparison of clinical pharmacology of voriconazole and posaconazole |
title_short |
Comparison of clinical pharmacology of voriconazole and posaconazole |
title_full |
Comparison of clinical pharmacology of voriconazole and posaconazole |
title_fullStr |
Comparison of clinical pharmacology of voriconazole and posaconazole |
title_full_unstemmed |
Comparison of clinical pharmacology of voriconazole and posaconazole |
title_sort |
comparison of clinical pharmacology of voriconazole and posaconazole |
publisher |
Termedia Publishing House |
series |
Contemporary Oncology |
issn |
1428-2526 1897-4309 |
publishDate |
2016-12-01 |
description |
Despite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal infections grows too. This is why there is still a quest for new antifungal drugs as well as for optimization of pharmacotherapy with already registered pharmaceutics.
Voriconazole and posaconazole are broad-spectrum, new generation, triazole antifungal agents. The drugs are used in the pharmacotherapy of invasive aspergillosis, Candida and Fusarium infections. Voriconazole is also used in infections caused by Scedosporium . Posaconazole is used in the treatment of coccidioidomycosis and chromoblastomycosis. Besides some similarities, the two mentioned drugs also show differences in therapeutic indications, pharmacokinetics (mainly absorption and metabolism), frequency and severity of adverse drug reactions, drug–drug interactions and dosage. As both of the drugs are used in the treatment of invasive fungal infections in adults and children, detailed knowledge of the clinical pharmacology of antifungal agents is the main factor in pharmacotherapy optimization in treatment of fungal infections.
The goal of the article is to present and compare the clinical pharmacology of voriconazole and posaconazole as well as to point out the indications and contraindications of using the drugs, determine factors influencing their pharmacotherapy, and provide information that
might be helpful in the treatment of fungal infections. |
topic |
voriconazole posaconazole clinical pharmacology cytochrome P-450 enzyme system drug monitoring |
url |
https://www.termedia.pl/Comparison-of-clinical-pharmacology-of-voriconazole-and-posaconazole,3,28897,1,1.html |
work_keys_str_mv |
AT beatamsienkiewicz comparisonofclinicalpharmacologyofvoriconazoleandposaconazole AT łukaszłapinski comparisonofclinicalpharmacologyofvoriconazoleandposaconazole AT annawielahojenska comparisonofclinicalpharmacologyofvoriconazoleandposaconazole |
_version_ |
1725714565085265920 |